Table 5.
Response | 200 mg bid (n = 13) | 400 mg bid (n = 14) | Total (n = 27) |
---|---|---|---|
Partial response | 1 | 0 | 1 (3.7%) |
Stable disease | 10 | 11 | 21 (77.8%) |
Progressive disease | 1 | 2 | 3 (11.1%) |
NA | 1 | 1 | 2 (7.4%) |
NA, not assessed because these patients did not complete cycle 1.